| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6561 | 2019 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ... The lancet Diabetes & endocrinology 7 (10), 776-785, 2019 | 1435 | 2019 |
| SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ... The Lancet 400 (10354), 757-767, 2022 | 645 | 2022 |
| Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ... Jama 323 (14), 1353-1368, 2020 | 517 | 2020 |
| Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ... Circulation 141 (2), 90-99, 2020 | 382 | 2020 |
| Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF) MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ... Circulation 143 (6), 516-525, 2021 | 378 | 2021 |
| Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF PS Jhund, SD Solomon, KF Docherty, HJL Heerspink, IS Anand, M Böhm, ... Circulation 143 (4), 298-309, 2021 | 284 | 2021 |
| Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, ... Nature medicine 28 (9), 1956-1964, 2022 | 244 | 2022 |
| Effects of dapagliflozin in DAPA-HF according to background heart failure therapy KF Docherty, PS Jhund, SE Inzucchi, L Køber, MN Kosiborod, FA Martinez, ... European heart journal 41 (25), 2379-2392, 2020 | 202 | 2020 |
| Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF JP Curtain, KF Docherty, PS Jhund, MC Petrie, SE Inzucchi, L Køber, ... European heart journal 42 (36), 3727-3738, 2021 | 184 | 2021 |
| Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction DD Berg, PS Jhund, KF Docherty, SA Murphy, S Verma, SE Inzucchi, ... JAMA cardiology 6 (5), 499-507, 2021 | 183 | 2021 |
| Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ... Circulation 142 (11), 1040-1054, 2020 | 176 | 2020 |
| Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short-and long-term outcomes E Platz, RT Campbell, B Claggett, EF Lewis, JD Groarke, KF Docherty, ... JACC: Heart Failure 7 (10), 849-858, 2019 | 176 | 2019 |
| Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF KF Docherty, M Vaduganathan, SD Solomon, JJV McMurray Heart Failure 8 (10), 800-810, 2020 | 137 | 2020 |
| Statin treatment of children with familial hypercholesterolemia–trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a … A Vuorio, KF Docherty, SE Humphries, J Kuoppala, PT Kovanen Atherosclerosis 226 (2), 315-320, 2013 | 131 | 2013 |
| Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF P McEwan, O Darlington, JJV McMurray, PS Jhund, KF Docherty, M Böhm, ... European journal of heart failure 22 (11), 2147-2156, 2020 | 122 | 2020 |
| Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) M Serenelli, M Böhm, SE Inzucchi, L Køber, MN Kosiborod, FA Martinez, ... European heart journal 41 (36), 3402-3418, 2020 | 122 | 2020 |
| Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial JH Butt, P Dewan, B Merkely, J Belohlávek, J Drożdż, M Kitakaze, ... Annals of internal medicine 175 (6), 820-830, 2022 | 109 | 2022 |
| Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF L Shen, SL Kristensen, O Bengtsson, M Böhm, RA de Boer, KF Docherty, ... Heart Failure 9 (4), 254-264, 2021 | 109 | 2021 |
| Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF C Adamson, KF Docherty, HJL Heerspink, RA de Boer, K Damman, ... Circulation 146 (6), 438-449, 2022 | 101 | 2022 |
